Hospital-Acquired Infection Diagnostics Market By Product (Instrument, Reagents and Consumables), By Test Type (Molecular Diagnostics, Immunoassay, Others), By Application (Disease Testing, Drug-Resistance Testing), By Infection Type (Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infections (UTI), Others), By End User (Hospital, Standalone Laboratories, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030

Hospital-Acquired Infection Diagnostics Market

Hospital-acquired infection, known as nosocomial infection, can occur in people who are admitted to hospitals or healthcare institutions for various reasons. Patients of all ages, from children to the elderly, who have undergone surgery, are susceptible to such illnesses. Gastrointestinal infection, surgical-site infection, respiratory infection, bloodstream infection, urinary tract infection, bone &joint infection, and cardiovascular system infection are the most prevalent infections. Nosocomial infection, also known as hospital-acquired infection, is an infection or toxin that exists in a specific location, such as a hospital, and can be contracted by a patient who visits or is admitted to the hospital for any reason other than this infection. The most prevalent wards where HAIs arise are intensive care units, or ICUs, where doctors treat critical conditions.

The expanding elderly population base, demand for HAI diagnostics from middle and low-income nations, and development of technologically improved diagnostic tools are all factors that drive the HAI diagnostics markets. Furthermore, the development of technologically improved diagnostic products that provide accurate and dependable results in a short amount of time is beneficial. The advancement of molecular diagnostics is being funded by major corporations. Many awareness campaigns have been launched by various governments and nonprofit organizations to reduce the number of people who die as a result of HAI, which is projected to create enough chances for the HAI diagnostics market to expand. The World Health Organization (WHO) launched a public awareness campaign called Patient Safety Solutions, in which the WHO emphasized hand hygiene as a top priority for health care facilities in order to reduce the number of infections.

The major factors that drive global hospital-acquired infection diagnostics market share are the rise in geriatric population, the development of technologically improved diagnostic technologies, and the need for HAI diagnostics in middle- and low-income nations. A rise in knowledge about hospital-acquired infections, a boom in R&D spending, enhanced healthcare infrastructure, technological improvements, and greater government actions around the world, all contribute to the expansion.

The hospital-acquired infection diagnostics market size is segmented on the basis of product, test type, application, infection type, end user, and region. By product, the industry is split into instrument &reagents and consumables. The reagents segment dominated the market. Growth of the segment is attributed to low awareness and high prevalence of hospital acquired infections in low and middle income countries. By test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. The molecular diagnosis segment dominated the market. The growth of the segment can be attributed to surge in infectious diseases, cancer, and sudden outbreak of pandemic. By application type, the market is bifurcated into disease testing and drug resistance testing. The drug-resistance testing segment dominated during the hospital-acquired infection diagnostics market forecast.

Furthermore, by infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI), and others. The respiratory infections segment dominated the market which is attributed to high prevalence of pneumonia in hospitalized patients. Depending on end users, the market is fragmented into hospitals, clinics, ambulatory surgery centres (ASC), and others. The hospital segment accounted for the largest segment in the market which was attributed to the outburst of pandemic and sudden surge of patients.

Region wise, North America dominated the global market in 2020 with a revenue of $1,550.81 million, which is attributed to increase in the geriatric population and adoption of advanced diagnostic equipment.

KEY FINDINGS OF STUDY

The study provides an in-depth analysis of the hospital acquired infections diagnostics market size along with the current hospital-acquired infection diagnostics market trends and future estimations to elucidate the imminent investment pockets.

It offers hospital acquired infections diagnostics market analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.

A comprehensive analysis of four regions is provided to determine the prevailing opportunities.

The profiles and growth strategies of the key players are thoroughly analysed to understand the competitive outlook and global hospital acquired infections diagnostics market growth.

Overview

The global hospital acquired infection diagnostics market was valued $3,355.28 million in 2020 and expected to reach $6,983.75 million by 2030, with a CAGR of 7.6% from 2021 to 2030.

Hospital-acquired illnesses, known as nosocomial infections, are infections acquired while in the hospital. Infections can be contracted at a hospital, nursing home, rehabilitation center, outpatient clinic, or other therapeutic setting. They can be obtained via an infected patient, the outside environment, or the facility's staff. The development in awareness among healthcare professionals and proposed government initiatives by several governmental organizations drive the growth of hospital-acquired infection diagnostics market. Furthermore, sanitation and hygiene are at a minimum in growing economies such as China, India, and Brazil. As a result, there are more hospital-acquired illnesses, driving up need for hospital-acquired infection diagnostics.

The expanding elderly population base, demand for HAI diagnostics from middle and low-income nations, and development of technologically improved diagnostic tools are all factors that drive the HAI diagnostics markets. Furthermore, the development of technologically improved diagnostic products that provide accurate and dependable results in a short amount of time is beneficial. The advancement of molecular diagnostics is being funded by major corporations. Many awareness campaigns have been launched by various governments and nonprofit organizations to reduce the number of people who die as a result of HAI, which is projected to create enough chances for the HAI diagnostics market to expand. The World Health Organization (WHO) launched a public awareness campaign called Patient Safety Solutions, in which the WHO emphasized hand hygiene as a top priority for health care facilities in order to reduce the number of infections.

The hospital-acquired infection diagnostics market is segmented on the basis of product, test type, application, infection type, end user, and region. By product, the industry is split into instrument & reagents and consumables. By test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. By application type, the market is bifurcated into disease testing and drug resistance testing.

Furthermore, by infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI), and others. Its end users include hospitals, clinics, ambulatory surgery centers (ASC), and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major key players that operate in the global hospital acquired infection diagnostics market are Abbott, Bayer, Becton Dickinson & Company, Danaher Corporation, Ecolab, Hologic, Johnson & Johnson, Merck Kgaa, Pfizer and Steris PLC.

 

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hospital-acquired infection diagnostics market analysis from 2020 to 2030 to identify the prevailing hospital-acquired infection diagnostics market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the hospital-acquired infection diagnostics market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global hospital-acquired infection diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

DANAHER CORPORATIO

Scope of Hospital-Acquired Infection Diagnostics Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Instrument

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Reagents and Consumables

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Molecular Diagnostics

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Immunoassay

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Others

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Disease Testing

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Drug-Resistance Testing

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 Hospital Acquired Pneumonia

7.2.1 Key market trends, growth factors and opportunities

7.2.2 Market size and forecast, by region

7.2.3 Market analysis by country

7.3 Bloodstream Infections

7.3.1 Key market trends, growth factors and opportunities

7.3.2 Market size and forecast, by region

7.3.3 Market analysis by country

7.4 Surgical Site Infections

7.4.1 Key market trends, growth factors and opportunities

7.4.2 Market size and forecast, by region

7.4.3 Market analysis by country

7.5 Gastrointestinal Infections

7.5.1 Key market trends, growth factors and opportunities

7.5.2 Market size and forecast, by region

7.5.3 Market analysis by country

7.6 Urinary Tract Infections (UTI)

7.6.1 Key market trends, growth factors and opportunities

7.6.2 Market size and forecast, by region

7.6.3 Market analysis by country

7.7 Others

7.7.1 Key market trends, growth factors and opportunities

7.7.2 Market size and forecast, by region

7.7.3 Market analysis by country

8.1 Overview

8.1.1 Market size and forecast

8.2 Hospital

8.2.1 Key market trends, growth factors and opportunities

8.2.2 Market size and forecast, by region

8.2.3 Market analysis by country

8.3 Standalone Laboratories

8.3.1 Key market trends, growth factors and opportunities

8.3.2 Market size and forecast, by region

8.3.3 Market analysis by country

8.4 Others

8.4.1 Key market trends, growth factors and opportunities

8.4.2 Market size and forecast, by region

8.4.3 Market analysis by country

9.1 Overview

9.1.1 Market size and forecast

9.2 North America

9.2.1 Key trends and opportunities

9.2.2 North America Market size and forecast, by By Product

9.2.3 North America Market size and forecast, by By Test Type

9.2.4 North America Market size and forecast, by By Application

9.2.5 North America Market size and forecast, by By Infection Type

9.2.6 North America Market size and forecast, by End User

9.2.7 North America Market size and forecast, by country

9.2.7.1 U.S.

9.2.7.1.1 Market size and forecast, by By Product

9.2.7.1.2 Market size and forecast, by By Test Type

9.2.7.1.3 Market size and forecast, by By Application

9.2.7.1.4 Market size and forecast, by By Infection Type

9.2.7.1.5 Market size and forecast, by End User

9.2.7.2 Canada

9.2.7.2.1 Market size and forecast, by By Product

9.2.7.2.2 Market size and forecast, by By Test Type

9.2.7.2.3 Market size and forecast, by By Application

9.2.7.2.4 Market size and forecast, by By Infection Type

9.2.7.2.5 Market size and forecast, by End User

9.2.7.3 Mexico

9.2.7.3.1 Market size and forecast, by By Product

9.2.7.3.2 Market size and forecast, by By Test Type

9.2.7.3.3 Market size and forecast, by By Application

9.2.7.3.4 Market size and forecast, by By Infection Type

9.2.7.3.5 Market size and forecast, by End User

9.3 Europe

9.3.1 Key trends and opportunities

9.3.2 Europe Market size and forecast, by By Product

9.3.3 Europe Market size and forecast, by By Test Type

9.3.4 Europe Market size and forecast, by By Application

9.3.5 Europe Market size and forecast, by By Infection Type

9.3.6 Europe Market size and forecast, by End User

9.3.7 Europe Market size and forecast, by country

9.3.7.1 Germany

9.3.7.1.1 Market size and forecast, by By Product

9.3.7.1.2 Market size and forecast, by By Test Type

9.3.7.1.3 Market size and forecast, by By Application

9.3.7.1.4 Market size and forecast, by By Infection Type

9.3.7.1.5 Market size and forecast, by End User

9.3.7.2 France

9.3.7.2.1 Market size and forecast, by By Product

9.3.7.2.2 Market size and forecast, by By Test Type

9.3.7.2.3 Market size and forecast, by By Application

9.3.7.2.4 Market size and forecast, by By Infection Type

9.3.7.2.5 Market size and forecast, by End User

9.3.7.3 U.K.

9.3.7.3.1 Market size and forecast, by By Product

9.3.7.3.2 Market size and forecast, by By Test Type

9.3.7.3.3 Market size and forecast, by By Application

9.3.7.3.4 Market size and forecast, by By Infection Type

9.3.7.3.5 Market size and forecast, by End User

9.3.7.4 Italy

9.3.7.4.1 Market size and forecast, by By Product

9.3.7.4.2 Market size and forecast, by By Test Type

9.3.7.4.3 Market size and forecast, by By Application

9.3.7.4.4 Market size and forecast, by By Infection Type

9.3.7.4.5 Market size and forecast, by End User

9.3.7.5 Spain

9.3.7.5.1 Market size and forecast, by By Product

9.3.7.5.2 Market size and forecast, by By Test Type

9.3.7.5.3 Market size and forecast, by By Application

9.3.7.5.4 Market size and forecast, by By Infection Type

9.3.7.5.5 Market size and forecast, by End User

9.3.7.6 Rest of Europe

9.3.7.6.1 Market size and forecast, by By Product

9.3.7.6.2 Market size and forecast, by By Test Type

9.3.7.6.3 Market size and forecast, by By Application

9.3.7.6.4 Market size and forecast, by By Infection Type

9.3.7.6.5 Market size and forecast, by End User

9.4 Asia-Pacific

9.4.1 Key trends and opportunities

9.4.2 Asia-Pacific Market size and forecast, by By Product

9.4.3 Asia-Pacific Market size and forecast, by By Test Type

9.4.4 Asia-Pacific Market size and forecast, by By Application

9.4.5 Asia-Pacific Market size and forecast, by By Infection Type

9.4.6 Asia-Pacific Market size and forecast, by End User

9.4.7 Asia-Pacific Market size and forecast, by country

9.4.7.1 Japan

9.4.7.1.1 Market size and forecast, by By Product

9.4.7.1.2 Market size and forecast, by By Test Type

9.4.7.1.3 Market size and forecast, by By Application

9.4.7.1.4 Market size and forecast, by By Infection Type

9.4.7.1.5 Market size and forecast, by End User

9.4.7.2 China

9.4.7.2.1 Market size and forecast, by By Product

9.4.7.2.2 Market size and forecast, by By Test Type

9.4.7.2.3 Market size and forecast, by By Application

9.4.7.2.4 Market size and forecast, by By Infection Type

9.4.7.2.5 Market size and forecast, by End User

9.4.7.3 Australia

9.4.7.3.1 Market size and forecast, by By Product

9.4.7.3.2 Market size and forecast, by By Test Type

9.4.7.3.3 Market size and forecast, by By Application

9.4.7.3.4 Market size and forecast, by By Infection Type

9.4.7.3.5 Market size and forecast, by End User

9.4.7.4 India

9.4.7.4.1 Market size and forecast, by By Product

9.4.7.4.2 Market size and forecast, by By Test Type

9.4.7.4.3 Market size and forecast, by By Application

9.4.7.4.4 Market size and forecast, by By Infection Type

9.4.7.4.5 Market size and forecast, by End User

9.4.7.5 South Korea

9.4.7.5.1 Market size and forecast, by By Product

9.4.7.5.2 Market size and forecast, by By Test Type

9.4.7.5.3 Market size and forecast, by By Application

9.4.7.5.4 Market size and forecast, by By Infection Type

9.4.7.5.5 Market size and forecast, by End User

9.4.7.6 Rest of LAMEA

9.4.7.6.1 Market size and forecast, by By Product

9.4.7.6.2 Market size and forecast, by By Test Type

9.4.7.6.3 Market size and forecast, by By Application

9.4.7.6.4 Market size and forecast, by By Infection Type

9.4.7.6.5 Market size and forecast, by End User

9.5 LAMEA

9.5.1 Key trends and opportunities

9.5.2 LAMEA Market size and forecast, by By Product

9.5.3 LAMEA Market size and forecast, by By Test Type

9.5.4 LAMEA Market size and forecast, by By Application

9.5.5 LAMEA Market size and forecast, by By Infection Type

9.5.6 LAMEA Market size and forecast, by End User

9.5.7 LAMEA Market size and forecast, by country

9.5.7.1 Brazil

9.5.7.1.1 Market size and forecast, by By Product

9.5.7.1.2 Market size and forecast, by By Test Type

9.5.7.1.3 Market size and forecast, by By Application

9.5.7.1.4 Market size and forecast, by By Infection Type

9.5.7.1.5 Market size and forecast, by End User

9.5.7.2 Saudi Arabia

9.5.7.2.1 Market size and forecast, by By Product

9.5.7.2.2 Market size and forecast, by By Test Type

9.5.7.2.3 Market size and forecast, by By Application

9.5.7.2.4 Market size and forecast, by By Infection Type

9.5.7.2.5 Market size and forecast, by End User

9.5.7.3 South Africa

9.5.7.3.1 Market size and forecast, by By Product

9.5.7.3.2 Market size and forecast, by By Test Type

9.5.7.3.3 Market size and forecast, by By Application

9.5.7.3.4 Market size and forecast, by By Infection Type

9.5.7.3.5 Market size and forecast, by End User

9.5.7.4 Rest of LAMEA

9.5.7.4.1 Market size and forecast, by By Product

9.5.7.4.2 Market size and forecast, by By Test Type

9.5.7.4.3 Market size and forecast, by By Application

9.5.7.4.4 Market size and forecast, by By Infection Type

9.5.7.4.5 Market size and forecast, by End User

10.1. Introduction

10.2. Top winning strategies

10.3. Product Mapping of Top 10 Player

10.4. Competitive Dashboard

10.5. Competitive Heatmap

10.6. Key developments

11.1 ABBOTT LABORATORIES

11.1.1 Company overview

11.1.2 Company snapshot

11.1.3 Operating business segments

11.1.4 Product portfolio

11.1.5 Business performance

11.1.6 Key strategic moves and developments

11.2 ECOLAB

11.2.1 Company overview

11.2.2 Company snapshot

11.2.3 Operating business segments

11.2.4 Product portfolio

11.2.5 Business performance

11.2.6 Key strategic moves and developments

11.3 JOHNSON & JOHNSON

11.3.1 Company overview

11.3.2 Company snapshot

11.3.3 Operating business segments

11.3.4 Product portfolio

11.3.5 Business performance

11.3.6 Key strategic moves and developments

11.4 MERCK KGaA

11.4.1 Company overview

11.4.2 Company snapshot

11.4.3 Operating business segments

11.4.4 Product portfolio

11.4.5 Business performance

11.4.6 Key strategic moves and developments

11.5 BAYER SCHERING PHARMA LLC

11.5.1 Company overview

11.5.2 Company snapshot

11.5.3 Operating business segments

11.5.4 Product portfolio

11.5.5 Business performance

11.5.6 Key strategic moves and developments

11.6 BECTON DICKINSON AND COMPANY

11.6.1 Company overview

11.6.2 Company snapshot

11.6.3 Operating business segments

11.6.4 Product portfolio

11.6.5 Business performance

11.6.6 Key strategic moves and developments

11.7 PFIZER INC.

11.7.1 Company overview

11.7.2 Company snapshot

11.7.3 Operating business segments

11.7.4 Product portfolio

11.7.5 Business performance

11.7.6 Key strategic moves and developments

11.8 STERIS PLC

11.8.1 Company overview

11.8.2 Company snapshot

11.8.3 Operating business segments

11.8.4 Product portfolio

11.8.5 Business performance

11.8.6 Key strategic moves and developments

11.9 HOLOGIC, INC.

11.9.1 Company overview

11.9.2 Company snapshot

11.9.3 Operating business segments

11.9.4 Product portfolio

11.9.5 Business performance

11.9.6 Key strategic moves and developments

11.10 DANAHER CORPORATION

11.10.1 Company overview

11.10.2 Company snapshot

11.10.3 Operating business segments

11.10.4 Product portfolio

11.10.5 Business performance

11.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY PRODUCT, 2020-2030,($MILLION)

TABLE 2. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR INSTRUMENT, BY REGION , 2020-2030,($MILLION)

TABLE 3. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET INSTRUMENT BY COUNTRY, 2020-2030,($MILLION)

TABLE 4. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR REAGENTS AND CONSUMABLES, BY REGION , 2020-2030,($MILLION)

TABLE 5. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REAGENTS AND CONSUMABLES BY COUNTRY, 2020-2030,($MILLION)

TABLE 6. GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY TEST TYPE, 2020-2030,($MILLION)

TABLE 7. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR MOLECULAR DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)

TABLE 8. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET MOLECULAR DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)

TABLE 9. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR IMMUNOASSAY, BY REGION , 2020-2030,($MILLION)

TABLE 10. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET IMMUNOASSAY BY COUNTRY, 2020-2030,($MILLION)

TABLE 11. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)

TABLE 12. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)

TABLE 13. GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY APPLICATION, 2020-2030,($MILLION)

TABLE 14. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR DISEASE TESTING, BY REGION , 2020-2030,($MILLION)

TABLE 15. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET DISEASE TESTING BY COUNTRY, 2020-2030,($MILLION)

TABLE 16. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR DRUG-RESISTANCE TESTING, BY REGION , 2020-2030,($MILLION)

TABLE 17. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET DRUG-RESISTANCE TESTING BY COUNTRY, 2020-2030,($MILLION)

TABLE 18. GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY INFECTION TYPE, 2020-2030,($MILLION)

TABLE 19. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR HOSPITAL ACQUIRED PNEUMONIA, BY REGION , 2020-2030,($MILLION)

TABLE 20. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET HOSPITAL ACQUIRED PNEUMONIA BY COUNTRY, 2020-2030,($MILLION)

TABLE 21. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR BLOODSTREAM INFECTIONS, BY REGION , 2020-2030,($MILLION)

TABLE 22. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BLOODSTREAM INFECTIONS BY COUNTRY, 2020-2030,($MILLION)

TABLE 23. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR SURGICAL SITE INFECTIONS, BY REGION , 2020-2030,($MILLION)

TABLE 24. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SURGICAL SITE INFECTIONS BY COUNTRY, 2020-2030,($MILLION)

TABLE 25. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR GASTROINTESTINAL INFECTIONS, BY REGION , 2020-2030,($MILLION)

TABLE 26. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET GASTROINTESTINAL INFECTIONS BY COUNTRY, 2020-2030,($MILLION)

TABLE 27. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR URINARY TRACT INFECTIONS (UTI), BY REGION , 2020-2030,($MILLION)

TABLE 28. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET URINARY TRACT INFECTIONS (UTI) BY COUNTRY, 2020-2030,($MILLION)

TABLE 29. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)

TABLE 30. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)

TABLE 31. GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 32. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR HOSPITAL, BY REGION , 2020-2030,($MILLION)

TABLE 33. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET HOSPITAL BY COUNTRY, 2020-2030,($MILLION)

TABLE 34. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR STANDALONE LABORATORIES, BY REGION , 2020-2030,($MILLION)

TABLE 35. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET STANDALONE LABORATORIES BY COUNTRY, 2020-2030,($MILLION)

TABLE 36. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)

TABLE 37. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)

TABLE 38. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY REGION, 2020-2030,($MILLION)

TABLE 39. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY PRODUCT, 2020-2030,($MILLION)

TABLE 40. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY TEST TYPE, 2020-2030,($MILLION)

TABLE 41. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY APPLICATION, 2020-2030,($MILLION)

TABLE 42. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY INFECTION TYPE, 2020-2030,($MILLION)

TABLE 43. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 44. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 45. U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 46. U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 47. U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 48. U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 49. U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 50. CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 51. CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 52. CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 53. CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 54. CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 55. MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 56. MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 57. MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 58. MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 59. MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 60. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY PRODUCT, 2020-2030,($MILLION)

TABLE 61. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY TEST TYPE, 2020-2030,($MILLION)

TABLE 62. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY APPLICATION, 2020-2030,($MILLION)

TABLE 63. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY INFECTION TYPE, 2020-2030,($MILLION)

TABLE 64. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 65. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 66. GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 67. GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 68. GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 69. GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 70. GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 71. FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 72. FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 73. FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 74. FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 75. FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 76. U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 77. U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 78. U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 79. U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 80. U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 81. ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 82. ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 83. ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 84. ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 85. ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 86. SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 87. SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 88. SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 89. SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 90. SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 91. REST OF EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 92. REST OF EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 93. REST OF EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 94. REST OF EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 95. REST OF EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 96. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY PRODUCT, 2020-2030,($MILLION)

TABLE 97. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY TEST TYPE, 2020-2030,($MILLION)

TABLE 98. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY APPLICATION, 2020-2030,($MILLION)

TABLE 99. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY INFECTION TYPE, 2020-2030,($MILLION)

TABLE 100. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 101. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 102. JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 103. JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 104. JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 105. JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 106. JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 107. CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 108. CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 109. CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 110. CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 111. CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 112. AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 113. AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 114. AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 115. AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 116. AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 117. INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 118. INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 119. INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 120. INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 121. INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 122. SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 123. SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 124. SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 125. SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 126. SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 127. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 128. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 129. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 130. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 131. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 132. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY PRODUCT, 2020-2030,($MILLION)

TABLE 133. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY TEST TYPE, 2020-2030,($MILLION)

TABLE 134. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY APPLICATION, 2020-2030,($MILLION)

TABLE 135. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY INFECTION TYPE, 2020-2030,($MILLION)

TABLE 136. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 137. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 138. BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 139. BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 140. BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 141. BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 142. BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 143. SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 144. SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 145. SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 146. SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 147. SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 148. SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 149. SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 150. SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 151. SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 152. SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 153. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)

TABLE 154. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)

TABLE 155. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)

TABLE 156. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 157. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 158.ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 159.ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 160.ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 161.ABBOTT LABORATORIES: NET SALES,

TABLE 162.ABBOTT LABORATORIES: KEY STRATERGIES

TABLE 163.ECOLAB: COMPANY SNAPSHOT

TABLE 164.ECOLAB: OPERATING SEGMENTS

TABLE 165.ECOLAB: PRODUCT PORTFOLIO

TABLE 166.ECOLAB: NET SALES,

TABLE 167.ECOLAB: KEY STRATERGIES

TABLE 168.JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 169.JOHNSON & JOHNSON: OPERATING SEGMENTS

TABLE 170.JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 171.JOHNSON & JOHNSON: NET SALES,

TABLE 172.JOHNSON & JOHNSON: KEY STRATERGIES

TABLE 173.MERCK KGAA: COMPANY SNAPSHOT

TABLE 174.MERCK KGAA: OPERATING SEGMENTS

TABLE 175.MERCK KGAA: PRODUCT PORTFOLIO

TABLE 176.MERCK KGAA: NET SALES,

TABLE 177.MERCK KGAA: KEY STRATERGIES

TABLE 178.BAYER SCHERING PHARMA LLC: COMPANY SNAPSHOT

TABLE 179.BAYER SCHERING PHARMA LLC: OPERATING SEGMENTS

TABLE 180.BAYER SCHERING PHARMA LLC: PRODUCT PORTFOLIO

TABLE 181.BAYER SCHERING PHARMA LLC: NET SALES,

TABLE 182.BAYER SCHERING PHARMA LLC: KEY STRATERGIES

TABLE 183.BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT

TABLE 184.BECTON DICKINSON AND COMPANY: OPERATING SEGMENTS

TABLE 185.BECTON DICKINSON AND COMPANY: PRODUCT PORTFOLIO

TABLE 186.BECTON DICKINSON AND COMPANY: NET SALES,

TABLE 187.BECTON DICKINSON AND COMPANY: KEY STRATERGIES

TABLE 188.PFIZER INC.: COMPANY SNAPSHOT

TABLE 189.PFIZER INC.: OPERATING SEGMENTS

TABLE 190.PFIZER INC.: PRODUCT PORTFOLIO

TABLE 191.PFIZER INC.: NET SALES,

TABLE 192.PFIZER INC.: KEY STRATERGIES

TABLE 193.STERIS PLC: COMPANY SNAPSHOT

TABLE 194.STERIS PLC: OPERATING SEGMENTS

TABLE 195.STERIS PLC: PRODUCT PORTFOLIO

TABLE 196.STERIS PLC: NET SALES,

TABLE 197.STERIS PLC: KEY STRATERGIES

TABLE 198.HOLOGIC, INC.: COMPANY SNAPSHOT

TABLE 199.HOLOGIC, INC.: OPERATING SEGMENTS

TABLE 200.HOLOGIC, INC.: PRODUCT PORTFOLIO

TABLE 201.HOLOGIC, INC.: NET SALES,

TABLE 202.HOLOGIC, INC.: KEY STRATERGIES

TABLE 203.DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 204.DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 205.DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 206.DANAHER CORPORATION: NET SALES,

TABLE 207.DANAHER CORPORATION: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SEGMENTATION

FIGURE 2.HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030

FIGURE 3.HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,BY BY PRODUCT,2020(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INSTRUMENT HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF REAGENTS AND CONSUMABLES HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 15.HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,BY BY TEST TYPE,2020(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF MOLECULAR DIAGNOSTICS HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF IMMUNOASSAY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 19.HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,BY BY APPLICATION,2020(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DISEASE TESTING HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF DRUG-RESISTANCE TESTING HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 22.HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,BY BY INFECTION TYPE,2020(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITAL ACQUIRED PNEUMONIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 24.COMPARATIVE SHARE ANALYSIS OF BLOODSTREAM INFECTIONS HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 25.COMPARATIVE SHARE ANALYSIS OF SURGICAL SITE INFECTIONS HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 26.COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL INFECTIONS HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 27.COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTIONS (UTI) HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 28.COMPARATIVE SHARE ANALYSIS OF OTHERS HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 29.HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,BY END USER,2020(%)

FIGURE 30.COMPARATIVE SHARE ANALYSIS OF HOSPITAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 31.COMPARATIVE SHARE ANALYSIS OF STANDALONE LABORATORIES HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 32.COMPARATIVE SHARE ANALYSIS OF OTHERS HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 33.HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY REGION,2020

FIGURE 34.U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 35.CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 36.MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 37.GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 38.FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 39.U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 40.ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 41.SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 42.REST OF EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 43.JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 44.CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 45.AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 46.INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 47.SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 48.REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 49.BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 50.SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 51.SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 52.REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 53. TOP WINNING STRATEGIES, BY YEAR

FIGURE 54. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 55. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 56.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 57.COMPETITIVE DASHBOARD

FIGURE 58.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 59.ABBOTT LABORATORIES.: NET SALES ,($MILLION)

FIGURE 60.ECOLAB.: NET SALES ,($MILLION)

FIGURE 61.JOHNSON & JOHNSON.: NET SALES ,($MILLION)

FIGURE 62.MERCK KGAA.: NET SALES ,($MILLION)

FIGURE 63.BAYER SCHERING PHARMA LLC.: NET SALES ,($MILLION)

FIGURE 64.BECTON DICKINSON AND COMPANY.: NET SALES ,($MILLION)

FIGURE 65.PFIZER INC..: NET SALES ,($MILLION)

FIGURE 66.STERIS PLC.: NET SALES ,($MILLION)

FIGURE 67.HOLOGIC, INC..: NET SALES ,($MILLION)

FIGURE 68.DANAHER CORPORATION.: NET SALES ,($MILLION